术中植入氟尿嘧啶缓释剂对大肝癌术后复发的影响-东南大学学报医学版

术中植入氟尿嘧啶缓释剂对大肝癌术后复发的影响

单位：南京医科大学附属淮安第一医院普外科, 江苏淮安 223300

分类号：R735.7

出版年·卷·期（页码）：2015·34·第一期（44-46）

摘要：

目的:研究术中植入氟尿嘧啶缓释剂对大肝癌术后复发的预防作用。方法:对我院收治的100例大肝癌手术患者进行前瞻性临床随机对照研究,分为实验组和对照组,各50例。实验组在术中行肝切除创面和大网膜氟尿嘧啶缓释剂植入。观察两组术前一般资料,术后肝肾功能,出血、胆漏、切口裂开等手术并发症,恶心呕吐、白细胞下降等化疗不良反应,以及1年、3年复发率和生存时间。结果:两组间术后手术并发症、化疗相关不良反应差异均无统计学意义(均P>0.05)。实验组1年、3年的复发率分别为34%和54%,对照组分别为42%和70%,两组间差异无统计学意义(P>0.05)。两组生存函数间差异有统计学意义(P<0.05)。结论:术中植入缓释型氟尿嘧啶安全可行,可延长患者生存时间。

Objective: To explore the effect of implanting sustained-release 5-fluorouracil during hepatectomy on the recurrence of large liver cancer.Methods:100 liver cancer patients undergoing hepatectomy were divided into experimental group(n=50) and control group(n=50). Operative complications, adverse reaction of chemotherapy, recurrence rate and survival time were compared between the two groups. Results: There were no difference in operative complications and adverse reaction of chemotherapy between the two groups. All the cases were followed up for more than 3 years. 1-, 3-year recurrence rates were 34% and 54% in experimental group respectively, 42% and 70% in control group respectively. There were no difference between them(P>0.05). Survival time of experimental group was longer than control group with statistical difference(P<0.05). Conclusion: Implanting sustained-release 5-fluorouracil can be used saftly during large liver cancer operation and can prolong survival time.

参考文献：

[1] KAMIYAMA T,NAKANISHI K,YOKOO H,et al.Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma[J].World J Surg Oncol,2012,10:1-7.
[2] 张必翔,陈孝平.大肝癌个体化外科综合治疗应重视的关键问题[J].外科理论与实践,2012,17(5):420-422.
[3] 马骖,单宏杰,包召玉,等.进展期胃癌术中植入5-氟尿嘧啶缓释剂的临床观察[J].中国肿瘤外科杂志,2013,5(1):58-60.
[4] MATSUI Y,TERAKAWA N,SATOI S,et al.Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface:clinical role of the no-margin resection[J].Arch Surg,2007,142(7):596-602.
[5] ZHOU Y M,YANG J M,LI B,et al.Risk factors for early recurrence of small hepatocellular carcinoma after curative resection[J].Hepatobiliary Pancreat Dis Int,2010,9(1):33-37.
[6] POON R T,FAN S T,NG I O,et al.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J].Cancer,2000,89(3):500-507.
[7] HASEGAWA K,MAKUUCHI M,KOKUDO N,et al.Impact of histologically confirmed lymph node metastaseson patient survival after surgical resection for hepatocellular carcinoma:report of a Japanese nationwide survey[J].Ann Surg,2014,259(1):166-170.
[8] ERCOLANI G,GRAZI G L,RAVAIOLI M,et al.The role of lymphadenectomy for liver tumors:further considerations on the appropriateness of treatment strategy[J].Ann Surg,2004,239(2):202-209.
[9] 陈荔,滕皋军.TACE对原发性肝癌肝功能的损伤[J].东南大学学报:医学版,2012,31(5):643-647.
[10] 邱少敏,陈刚,李宏波.肝动脉化疗栓塞联合经皮微波凝固疗法治疗中晚期肝癌的临床观察[J].现代医学,2011,39(5):526-529.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录